Caris Life Sciences Inc (CAI): Next-Year EPS Estimate 168.04%
As of 2026-06-04, Caris Life Sciences Inc (CAI) has a next-year EPS growth estimate of 168.04%.
On 2026-06-03, analyst consensus for CAI's next-year EPS growth shifted from 151.75% to 168.04% — a positive change of 16.29 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 132.69%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 168.04%
- EPS growth this year
- 132.69%
- EPS next quarter (est)
- $0.02
- Last price
- $17.28
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 168.04% | 132.69% | $0.02 | $17.28 |
| 2026-06-03 | 168.04% | 132.69% | $0.02 | $15.48 |
| 2026-06-02 | 151.75% | 135.29% | $0.02 | $16.52 |
| 2026-06-01 | 159.23% | 134.99% | $0.01 | $16.45 |
| 2026-05-31 | 159.23% | 134.99% | $0.01 | $16.72 |
| 2026-05-28 | 159.23% | 134.99% | $0.01 | $16.67 |
| 2026-05-27 | 159.23% | 134.99% | $0.01 | $15.38 |
| 2026-05-26 | 159.23% | 134.99% | $0.01 | $15.52 |
| 2026-05-25 | 159.23% | 134.99% | $0.01 | $15.55 |
| 2026-05-24 | 159.23% | 134.99% | $0.01 | $15.55 |
| 2026-05-21 | 159.23% | 134.99% | $0.01 | $15.94 |
| 2026-05-20 | 159.23% | 134.99% | $0.01 | $15.70 |
| 2026-05-19 | 159.23% | 134.99% | $0.01 | $14.96 |
| 2026-05-18 | 159.23% | 134.99% | $0.01 | $15.10 |
| 2026-05-17 | 159.23% | 134.99% | $0.01 | $14.55 |
| 2026-05-14 | 159.23% | 134.99% | $0.01 | $15.25 |
| 2026-05-13 | 159.23% | 134.99% | $0.01 | $14.42 |
| 2026-05-12 | 159.23% | 134.99% | $0.01 | $16.76 |
| 2026-05-11 | 162.74% | 134.70% | $0.01 | $15.94 |
| 2026-05-10 | 182.86% | 132.66% | $0.02 | $16.15 |
| 2026-05-07 | 214.43% | 129.80% | -$0.02 | $19.84 |
| 2026-05-06 | 226.41% | 129.40% | -$0.03 | $19.13 |
| 2026-05-05 | 226.41% | 129.40% | -$0.03 | $18.95 |
| 2026-05-04 | 226.41% | 129.40% | -$0.03 | $18.69 |
| 2026-05-03 | 226.41% | 129.40% | -$0.03 | $18.47 |
| 2026-04-30 | 224.91% | 129.59% | -$0.03 | $19.00 |
| 2026-04-29 | 224.91% | 129.59% | -$0.03 | $17.77 |
| 2026-04-28 | 224.91% | 129.59% | -$0.03 | $18.44 |
| 2026-04-27 | 224.91% | 129.59% | -$0.03 | $19.93 |
| 2026-04-26 | 224.91% | 129.59% | -$0.03 | $20.20 |
Recent News
- Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026PR Newswire
- Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC PatientsPR Newswire
- Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung CancerPR Newswire
- Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung CancerPR Newswire
- Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026PR Newswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Caris Life Sciences Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Caris Life Sciences Inc (CAI) has a next-year EPS growth estimate of 168.04%, based on analyst consensus.
When was the latest EPS estimate revision for CAI?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 151.75% to 168.04%.
What sector and industry does Caris Life Sciences Inc belong to?▾
Caris Life Sciences Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CAI appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Caris Life Sciences Inc (CAI) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports